![]() ![]() KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a CAR designed to target the antigen CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. For more information on Kite Pharma, please visit Sign up to follow on Twitter at About Kite's ZUMA Clinical Programs for KTE-C19 Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Presenter: Kenny Choi, Kite Pharma, Santa Monica, CA Location: Exhibit Hall C & B South, Marriott Wardman Park ![]() Session: Cancer-Immunotherapy, Cancer Vaccines III Presenter: Frederick Locke, M.D., Moffitt Cancer Center, Tampa, FLĭevelopment of a Manufacturing Process Using Monte Carlo Simulations to Support KTE-C19 (Anti-CD19 CAR T Cells) Studies in Leukemia Location: Thurgood Marshall North, Marriott Wardman Park Session: Cancer-Immunotherapy, Cancer Vaccines III (10:15AM-12:15PM Eastern Time) Updated Phase 1 Results from ZUMA-1: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 (Anti-CD19 CAR T Cells) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)ĭate: Saturday, 10:15-10:30AM Eastern Time Presenter: Marc Better, Ph.D., Kite Pharma, Santa Monica, CA Session: Vector and Cell Engineering/Manufacturing (4:00-5:45PM Eastern Time) Production of KTE-C19 (Anti-CD19 CAR T Cells) for ZUMA-1: A Phase 1/2 Multi-Center Study Evaluating Safety and Efficacy in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Presenter: Leah Alabanza, Ph.D., Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD Location: Washington 1-2, Marriott Wardman Park Session: Cancer-Targeted Gene and Cell Therapy (3:30-5:30PM Eastern Time) The Impact of Different Hinge and Transmembrane Components on the Function of a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptorĭate: Wednesday, 4:45-5:00PM Eastern Time Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI. Under this CRADA, Kite collaborates with James (Jim) N. The fully-human anti-CD19 CAR product candidate is currently being studied in an ongoing Phase 1 clinical trial as part of a Cooperative Research and Development Agreement (CRADA) between Kite and the National Cancer Institute (NCI). The presentations will address KTE-C19, Kite's lead chimeric antigen receptor (CAR) product candidate, and, separately, a fully-human anti-CD19 CAR product candidate for the treatment of B-cell lymphomas and leukemias. SANTA MONICA, Calif., Ap(GLOBE NEWSWIRE) - Kite Pharma, Inc., (Nasdaq:KITE) ('Kite') a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced four presentations to be delivered at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |